{"id":522059,"date":"2021-08-03T08:04:14","date_gmt":"2021-08-03T12:04:14","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/"},"modified":"2021-08-03T08:04:14","modified_gmt":"2021-08-03T12:04:14","slug":"pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/","title":{"rendered":"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference"},"content":{"rendered":"<div class=\"mw_release\">\n<p align=\"left\">SOUTH SAN FRANCISCO, Calif., Aug.  03, 2021  (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 BTIG Virtual Biotechnology Conference to be held August 9 \u2013 10, 2021.<\/p>\n<p>Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer, will participate in a fireside chat on Tuesday, August 10, 2021, at 3:30 p.m. EST \/ 12:30 p.m. PST and, along with members of Pliant\u2019s senior management team, will conduct one-on-one meetings with members of the investment community.<\/p>\n<p>\n        <strong>About\u00a0Pliant Therapeutics, Inc.<\/strong><\/p>\n<p>Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis. Pliant&#8217;s lead product candidate, PLN-74809, is an oral small molecule dual selective inhibitor of \u03b1<sub>v<\/sub>\u00df<sub>6<\/sub>\u00a0and \u03b1<sub>v<\/sub>\u00df<sub>1<\/sub>\u00a0integrins that is in development in the lead indications for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis, or PSC. PLN-74809 has received Orphan Drug Designation from the U.S. Food and Drug Administration for both IPF and PSC. Pliant is currently recruiting Phase 2a trials of PLN-74809 in the lead indications of IPF, PSC. Pliant has also developed PLN-1474, a small molecule selective inhibitor of \u03b1<sub>v<\/sub>\u00df<sub>1<\/sub> for the treatment of nonalcoholic steatohepatitis, or NASH with liver fibrosis, which Pliant has transferred to Novartis pursuant to our development partnership. In addition to clinical stage programs, Pliant currently has two preclinical programs targeting oncology and muscular dystrophies. For additional information about Pliant Therapeutics, visit\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=TYyTyW36dRyEOfkrsDyWD1eX7QbQp_OVPPnBZE5Y1PMFwcX48ZVFvtdI52iYPyokqqKlGLAkjZ88OmAXBNUQYzbjHToDWTd_xMMcaRzTnqz7WPvlz14FLItzZ6yuowjOV0QDT0GluLbMeHpgYFPmoSPi-zW6l5KZSW4w5FaNpi1yrMUz6Y3B8dVmFbSL7sTPndmH3GbmSc4mwFyUsWEgONbFcoqudSTstkJYurqTzt4=\" rel=\"nofollow noopener\" target=\"_blank\">www.pliantrx.com<\/a>\u00a0and follow us on\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=BDgNPMc4C0oaySW0eytAFwJ24UAzUIREa5UvtDZ9UUqmK4e7BqeMXCDzl-wxkQfkZqQ5rrDxk8vKadk5ZcDCq1ezeTS-yeuVnF-PpPBNWZ8mn7d__KI_n5R3QGmINUIIlbrSY0g-neWgHRfjxFWJgkuzLbowSLfbaTsLgkhcbDaxMQ-eq5YUswMS_m3_VXV7jX50oaugSdsX3NkfA23hYw==\" rel=\"nofollow noopener\" target=\"_blank\">Twitter<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=9JVtNOAXEL59H5cRWp18JUGbUvg50lHRpXMth4SuKKDWRrBdi_gedztlNT5JMrXCtYQHQjDtYkmpwMGB1XJQIx97vnGXopsCJBDkh8SvPaPgnxJBaHVTQhsBaqR2rKBh0YWzOgLfapzg0_eQBb1uhYI3xsc2QpCHPPoUca9LoJ0ruHJ33Ky10DIwRTMXB6shDrKVZdGRMMGlULCgWtLqEwRkCWkvW7oiERr7XrShz3ystVaHHQbyspgiRMZYumeIIHsm1o80ocOtnAg5yRHBrQ==\" rel=\"nofollow noopener\" target=\"_blank\">LinkedIn<\/a>,\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Zg4iVShLYjANa22NnZlXZ0oq1De_fC15khIEY6aw3kosQEuMU5dV2LHO_AiiIWAFaIv-IgP-7Hn4sNwsTVfz9cKf8YnKlfAib2BsVp2k-VPTs4_RVFpSpsDyzBbfj6RYq-30PXPrd46iQH0xTNxqeUVdlDm9Yd4srr46Z724w5seoxNZkcLFH3FPbKm9a1tP12af0p97VJtUVxn894ozQB3uTcaq4zbPMhttbDu3wak=\" rel=\"nofollow noopener\" target=\"_blank\">Facebook<\/a> and\u00a0<a href=\"https:\/\/www.globenewswire.com\/Tracker?data=Pvfbya8zjMXMnF1z0mG0WDFLk1dWFZ8jb9kYAGb71Lja-BZrwcKtbAoW8cGnhvkFp5PsbrK6jO3jZH4RrEAl3Hca3CJO16kUUlwRLFD6FluDpCisI58mO5twA67vdSkHfZx1Rc-0FT3m7-as2IsQEW1BYKAyZ5FLzAygHzpOhDYJuk3KRCoIyUp_3PKCMUpfaB1m4boIIcx8peA9MeIE27FiXA8hpCfb7HGEbvRNn1i0qzyabfkTlsbhVQsal_5CEmW9JaYhwhCQDQ7BacjlNw==\" rel=\"nofollow noopener\" target=\"_blank\">YouTube<\/a>.<\/p>\n<p>\n        <strong>Investor and Media Contact:<\/strong><br \/>\n        <br \/>Christopher Keenan<br \/>Vice President, Investor Relations and Corporate Communications<br \/>Pliant Therapeutics, Inc.<br \/><u><a href=\"https:\/\/www.globenewswire.com\/Tracker?data=ATjum5Pe14YohmexC1aAg_lPErIZPKntGbfFtvLWnpOAG0mj-MIhd1VU5QB_ZtJV4bSq9zRsSdddE6nqmmG5Dg==\" rel=\"nofollow noopener\" target=\"_blank\">ir@pliantrx.com<\/a><\/u><\/p>\n<p>\u00a0<\/p>\n<p>      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY=\" width=\"1\" height=\"1\" \/><br \/>\n      <br \/>\n      <img loading=\"lazy\" decoding=\"async\" class=\"__GNW8366DE3E__IMG\" src=\"https:\/\/ml.globenewswire.com\/release\/track\/3dac5e98-5888-4901-a951-eadc26e6fb7f\" width=\"1\" height=\"1\" \/>\n    <\/div>\n<div class=\"mw_contactinfo\"><\/div>\n","protected":false},"excerpt":{"rendered":"<p>SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 BTIG Virtual Biotechnology Conference to be held August 9 \u2013 10, 2021. Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer, will participate in a fireside chat on Tuesday, August 10, 2021, at 3:30 p.m. EST \/ 12:30 p.m. PST and, along with members of Pliant\u2019s senior management team, will conduct one-on-one meetings with members of the investment community. About\u00a0Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment &hellip; <\/p>\n<p class=\"link-more\"><a href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/\" class=\"more-link\">Continue reading<span class=\"screen-reader-text\"> &#8220;Pliant Therapeutics to Participate in the BTIG Biotechnology Conference&#8221;<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-522059","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v27.5 - https:\/\/yoast.com\/product\/yoast-seo-wordpress\/ -->\n<title>Pliant Therapeutics to Participate in the BTIG Biotechnology Conference - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 BTIG Virtual Biotechnology Conference to be held August 9 \u2013 10, 2021. Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer, will participate in a fireside chat on Tuesday, August 10, 2021, at 3:30 p.m. EST \/ 12:30 p.m. PST and, along with members of Pliant\u2019s senior management team, will conduct one-on-one meetings with members of the investment community. About\u00a0Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment &hellip; Continue reading &quot;Pliant Therapeutics to Participate in the BTIG Biotechnology Conference&quot;\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2021-08-03T12:04:14+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference\",\"datePublished\":\"2021-08-03T12:04:14+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/\"},\"wordCount\":289,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/\",\"name\":\"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY=\",\"datePublished\":\"2021-08-03T12:04:14+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/","og_locale":"en_US","og_type":"article","og_title":"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference - Market Newsdesk","og_description":"SOUTH SAN FRANCISCO, Calif., Aug. 03, 2021 (GLOBE NEWSWIRE) &#8212; Pliant Therapeutics, Inc. (Nasdaq: PLRX), a clinical stage biotechnology company focused on discovering and developing novel therapeutics for the treatment of fibrosis, today announced its participation in the 2021 BTIG Virtual Biotechnology Conference to be held August 9 \u2013 10, 2021. Bernard Coulie, M.D., Ph.D., Pliant\u2019s President and Chief Executive Officer, will participate in a fireside chat on Tuesday, August 10, 2021, at 3:30 p.m. EST \/ 12:30 p.m. PST and, along with members of Pliant\u2019s senior management team, will conduct one-on-one meetings with members of the investment community. About\u00a0Pliant Therapeutics, Inc. Pliant Therapeutics is a clinical stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment &hellip; Continue reading \"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/","og_site_name":"Market Newsdesk","article_published_time":"2021-08-03T12:04:14+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference","datePublished":"2021-08-03T12:04:14+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/"},"wordCount":289,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/","name":"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY=","datePublished":"2021-08-03T12:04:14+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=ODMwMTQ3NiM0MzM3Nzg1IzIxODU0NzY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/pliant-therapeutics-to-participate-in-the-btig-biotechnology-conference\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Pliant Therapeutics to Participate in the BTIG Biotechnology Conference"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522059","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=522059"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/522059\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=522059"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=522059"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=522059"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}